Bernstein Harold 4

What Happened

• Harold Bernstein, President, R&D & Chief Medical Officer of Maze Therapeutics, exercised 15,000 options at $10.42 per share (cost $156,300) and the same day sold 15,000 shares at a weighted average price of $26.22 for total proceeds of $393,354 (May 14, 2026). The filing also reports a separate 15,000-share derivative disposition at $0.00 (see Key Details and Footnotes).

Key Details

• Transaction date: May 14, 2026; Form 4 filed May 18, 2026 (filed within the required two business days).
• Exercise (code M): 15,000 shares acquired at $10.42 — total cash outlay reported $156,300.
• Sale (code S): 15,000 shares sold at weighted average $26.22 — total proceeds reported $393,354. Sales occurred at prices ranging $25.77–$26.44 (see footnote F2).
• Derivative disposition (code M): 15,000 shares reported as disposed at $0.00 (reported as a derivative transaction).
• Footnotes: F1 — the sale was effected under a Rule 10b5-1 trading plan adopted Sept 29, 2025; F2 — weighted average sale price and range; F3 — option vesting schedule (1/4 on Oct 3, 2023, then monthly vesting thereafter).
• Shares owned after transaction: not disclosed in the provided filing details.

Context

• The sequence (exercise then immediate sale the same day) is consistent with a cashless exercise / immediate liquidity event — the 10b5-1 plan (F1) indicates the sale was pre-arranged rather than an ad hoc trade.
• The $0.00 derivative disposition may reflect an internal conversion/settlement reporting item; consult the filed Form 4 footnotes or contact the company for specifics.
• These transactions are routine insider liquidity events and, by themselves, do not necessarily indicate a change in insider sentiment.